Manager TitleAgeSince
Chief Operating Officer - -
Date Insider Type Main position Quantity % Market Cap.
22/06/23Free

Chairman

1,200 0.0049%
22/06/23Free

Director

1,200 0.0049%
22/06/23Free

Director

1,200 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-38.64% - - 16.77K
+1.28%+2.25%+65.45%+121.01% 55.35B
+1.58%+14.12%+72.87%+85.18% 51.92B
+0.22%-0.21%-15.20%-15.83% 22.76B
+2.01%+7.97%+4.64%+434.73% 22.64B
-0.18%+7.48%+32.16%-14.07% 17.36B
-1.53%+3.30%+27.83%-34.96% 16.1B
+3.02%+12.74%+143.33%+308.04% 13.96B
+3.16%+7.00%+27.51%+182.35% 13.38B
+1.31%+6.52%+28.62% - 12.27B
Average +0.68%+5.82%+43.02%+133.31% 25.08B
Weighted average by Cap. +1.16%+6.54%+48.25%+124.32%
Logo Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Employees
102
  1. Stock Market
  2. Stocks
  3. ACOR.Q Stock